A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources

Gillian Lockwood, Barbara Cometti, Jeanette Bogstad, Karin Erb, Christian De Geyter, J. Urbancsek, Silvia Trevisan, Khaled Pocate-Cheriet, Dominique de Ziegler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur®- Ferring and Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m2 or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS). No statistically significant differences between the treatment groups were reported for most of the clinically significant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95% CI of the difference equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent. The safety profile of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG preparation is a viable alternative for conducting ovarian stimulation in IVF cycles.

Original languageEnglish
Pages (from-to)17-27
Number of pages11
JournalReproductive BioMedicine Online
Volume35
Issue number1
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Oocytes
Randomized Controlled Trials
Safety
Ovulation Induction
Ovarian Hyperstimulation Syndrome
Menotropins
Reproductive Techniques
Birth Rate
Pregnancy Rate
Fertilization
Gonadotropin-Releasing Hormone
Down-Regulation
Embryonic Structures
Therapeutics

Keywords

  • Assisted reproduction
  • HCG
  • HMG
  • IVF
  • Ovarian stimulation

ASJC Scopus subject areas

  • Reproductive Medicine
  • Developmental Biology

Cite this

A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources. / Lockwood, Gillian; Cometti, Barbara; Bogstad, Jeanette; Erb, Karin; De Geyter, Christian; Urbancsek, J.; Trevisan, Silvia; Pocate-Cheriet, Khaled; de Ziegler, Dominique.

In: Reproductive BioMedicine Online, Vol. 35, No. 1, 01.07.2017, p. 17-27.

Research output: Contribution to journalArticle

Lockwood, Gillian ; Cometti, Barbara ; Bogstad, Jeanette ; Erb, Karin ; De Geyter, Christian ; Urbancsek, J. ; Trevisan, Silvia ; Pocate-Cheriet, Khaled ; de Ziegler, Dominique. / A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources. In: Reproductive BioMedicine Online. 2017 ; Vol. 35, No. 1. pp. 17-27.
@article{e164a7b005f944199f5c8e17fcd88fa3,
title = "A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources",
abstract = "In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur{\circledR}- Ferring and Meriofert{\circledR}- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m2 or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS). No statistically significant differences between the treatment groups were reported for most of the clinically significant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95{\%} CI of the difference equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent. The safety profile of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG preparation is a viable alternative for conducting ovarian stimulation in IVF cycles.",
keywords = "Assisted reproduction, HCG, HMG, IVF, Ovarian stimulation",
author = "Gillian Lockwood and Barbara Cometti and Jeanette Bogstad and Karin Erb and {De Geyter}, Christian and J. Urbancsek and Silvia Trevisan and Khaled Pocate-Cheriet and {de Ziegler}, Dominique",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.rbmo.2017.03.021",
language = "English",
volume = "35",
pages = "17--27",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources

AU - Lockwood, Gillian

AU - Cometti, Barbara

AU - Bogstad, Jeanette

AU - Erb, Karin

AU - De Geyter, Christian

AU - Urbancsek, J.

AU - Trevisan, Silvia

AU - Pocate-Cheriet, Khaled

AU - de Ziegler, Dominique

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur®- Ferring and Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m2 or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS). No statistically significant differences between the treatment groups were reported for most of the clinically significant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95% CI of the difference equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent. The safety profile of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG preparation is a viable alternative for conducting ovarian stimulation in IVF cycles.

AB - In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur®- Ferring and Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m2 or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS). No statistically significant differences between the treatment groups were reported for most of the clinically significant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95% CI of the difference equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent. The safety profile of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG preparation is a viable alternative for conducting ovarian stimulation in IVF cycles.

KW - Assisted reproduction

KW - HCG

KW - HMG

KW - IVF

KW - Ovarian stimulation

UR - http://www.scopus.com/inward/record.url?scp=85018953428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018953428&partnerID=8YFLogxK

U2 - 10.1016/j.rbmo.2017.03.021

DO - 10.1016/j.rbmo.2017.03.021

M3 - Article

C2 - 28476487

AN - SCOPUS:85018953428

VL - 35

SP - 17

EP - 27

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 1

ER -